Lobbying Information
Subject Matters
- Consumer Issues
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Science and Technology
- Small Business
- Taxation and Finance
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Provide input into the Government of Canada's negotiations regarding the Anti-Counterfeiting Trade Agreement and bilateral trade agreements with respect to pharmaceuticals, counterfeit medicines, and intellectual property.
- Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic Trade Agreement with respect to pharmaceuticals, counterfeit medicines, border measures, and intellectual property.
Policies or Program
- Industry Canada's Science & Technology strategy regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
- Patented Medicine Prices Review Board regarding claims of jurisdiction with respect to generic drug products associated with a patent.
- Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
- Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions
- Provide input into guidance with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders.
- Provide input into policy discussions regarding the potential development of a national pharmacare program governments.
- Providing input into the development and implementation of an approval pathway for Subsequent Entry Biologics by Health Canada.
- To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat counterfeit pharmaceutical both nationally and globally.
- participation in consultations, providing comments on modernization of the Food and Drugs Act and related regulations regarding pharmaceuticals
Regulation
- The need for amendments to the Patented Medicines (Notice of Compliance) Regulations of the Patent Act and address operational concerns such as bringing finality to proceedings under the Regulations; allowing generic manufacturers to amend a Notice of Allegation; and providing meaningful damages and other disincentives to discourage abuse of the Regulatioins by brand name manufacturers.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Canadian Heritage (PCH)
-
Canadian International Trade Tribunal (CITT)
-
Environment Canada
-
Finance Canada (FIN)
-
Foreign Affairs, Trade and Development Canada
-
Hazardous Materials Information Review Commission (HMIRC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Natural Resources Canada (NRCan)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
In-house Corporation Details
Description of activities
Provider of generic and specialty pharmaceuticals.
Responsible officer name and position during the period of this registration
Richard Guest,
Chief Executive Officer
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
85 Advance Road
Etobicoke, ON M8Z 2S6
Canada
Telephone number:
416-236-2631
Fax number:
416-236-9022
Parent Company Information
Mylan Pharmaceuticals ULC is not a subsidiary of any other parent companies.
Subsidiary Beneficiary Information
Mylan Pharmaceuticals ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Naguib Fahmy,
President |
No public offices held
- Joanne Manley,
Director, Regulatory Affairs |
No public offices held
- Bonnie Southorn,
Director, Regulatory Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Diane Bigras,
Senior Director, Gov't Relations and Market Access |
No public offices held
- Richard Guest,
Chief Executive Officer |
No public offices held